A prospective, randomized, open, multicentre phase III study to assess the efficacy of secondary adjuvant endocrine anastrozole therapy for 2 further yrs vs 5 further yrs in patients with HR +Ve breast cancer after 5-yr primary adjuvant endocrine therapy

Trial Profile

A prospective, randomized, open, multicentre phase III study to assess the efficacy of secondary adjuvant endocrine anastrozole therapy for 2 further yrs vs 5 further yrs in patients with HR +Ve breast cancer after 5-yr primary adjuvant endocrine therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Anastrozole (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms SALSA
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 09 Dec 2017 Primary endpoint (Assessment of the effect in terms of DFS of 2 further years of anastrozole treatment vs further 5 years of adjuvant anastrozole treatment, following 5 years of adjuvant endocrine treatment) has not been met, as per results presented at the 40th Annual San Antonio Breast Cancer Symposium.
    • 09 Dec 2017 Results presented at the 40th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top